Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) EPS (Weighted Average and Diluted) (2023 - 2025)

CG Oncology filings provide 3 years of EPS (Weighted Average and Diluted) readings, the most recent being -$0.51 for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 6.25% to -$0.51 in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.07, a 45.77% decrease, with the full-year FY2025 number at -$2.08, down 47.52% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.51 in Q4 2025 for CG Oncology, up from -$0.57 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.28 in Q2 2024 to a low of -$4.47 in Q4 2023.
  • Median EPS (Weighted Average and Diluted) over the past 3 years was -$0.52 (2025), compared with a mean of -$1.59.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): skyrocketed 92.88% in 2024 and later tumbled 92.86% in 2025.
  • CG Oncology's EPS (Weighted Average and Diluted) stood at -$4.47 in 2023, then soared by 89.26% to -$0.48 in 2024, then fell by 6.25% to -$0.51 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.51 (Q4 2025), -$0.57 (Q3 2025), and -$0.54 (Q2 2025) per Business Quant data.